The dietary isothiocyanates (ITCs) 
Introduction

Breast cancer ranks second in cancer-related deaths among women in the United States [1]. Endocrine therapies, such as tamoxifen and the aromatase inhibitors, are widely used for the treatment of hormone-sensitive advanced breast cancer and successfully lead to tumour regression or disease stabilization in approximately 70% of patients for a certain period of time [2]. Most patients gradually gain resistance to initial endocrine therapy, although many retain hormone sensitivity and respond to subsequent endocrine treatments such as Fulvestrant (Faslodex
® , ICI 182,780) [2]. ICI 182,780 (Fig. 1A) is a 'pure' anti-oestrogen, which induces degradation of oestrogen receptor-␣ (ER-␣) protein, decreases transactivation function of ER-␣ and leads to a reduction in expression levels of oestrogen-regulated genes potentially important for cell growth
. However, only 30% of patients who had progressed following prior aromatase inhibitor treatment gained clinical benefit from Fulvestrant with the median time to re-progression about 3.4 to 5.5 months [5, 6] . The object response rate was about 20.7% to 37% in advanced breast cancer of post-menopausal women whose disease progressed on prior endocrine therapy [5, 6] .
Recently, we cloned a novel 36 kD variant of the ER-␣, ER-␣36 [7, 8] [7, 8] . ER-␣36 mediates membrane-initiated oestrogen and antioestrogen signaling by activation of the mitogen activated protein kinase (MAPK) signaling pathway [7, 8] . The finding that ER-␣36 also mediates mitogenic anti-oestrogen signaling pathway may provide an alternative explanation for anti-oestrogen resistance observed in breast cancer patients undergoing anti-oestrogen therapy [9] .
. The original 66 kD ER-␣ is referred to as ER-␣66 hereafter. ER-␣36 differs from ER-␣66 by lacking both transcriptional activation domains (AF-1 and AF-2), but it retains the DNA-binding and dimerization domains, and partial ligand-binding domains
Epidemiological and pharmacological evidence demonstrate that dietary isothiocyanates (ITCs) have substantial chemopreventive activity against various types of cancers including breast cancer [10] [11] [12] [13] [14] . ITCs exist as conjugates in the genus Brassica of cruciferous vegetables and the genus Raphanus [15, 16] . ITCs also potently inhibit the malignant growth of cancer cells by inducing cell cycle arrest and apoptosis with little or no toxicity towards normal cells [17] [18] [19] . Phenethyl isothiocyanate (PEITC) (Fig. 1A) is one of the well-studied ITCs for their growth inhibitory functions in different cancer cells. PEITC was potent in inducing apoptosis and activating caspases in human bladder cancer cells and breast cancer cells [20, 21] (Fig. 5A, B (Fig. 5A, B Fig. 6A-D [7] . 
), suggesting that PEITC down-regulates the levels of ER-␣36 protein through the proteasome-dependent proteolysis pathway. We also examined the levels of ER-␣36 mRNA in MCF7 and H3396 cells treated with different concentrations of PEITC or ICI 182, 780 for 12 hrs by RT-PCR analysis. We found that mRNA levels of ER-␣36 in these breast cancer cells were unchanged after the treatment of PEITC or ICI 182, 780 (
PEITC induces ERK phosphorylation in ER-␣36 expressing cells
To further probe the molecular mechanisms by which PEITC downregulates ER-␣36, we used stable cell lines from HEK293 cells transfected with the empty expression vector (HEK293/V) and the expression vector for ER-␣36 (HEK293/36) established before
PEITC inhibits non-genomic oestrogen signaling in MCF7 cells
Recently, we demonstrated that ER-␣36 mediates non-genomic oestrogen signaling by activation of the MAPK/ERK signaling pathway [7] . (Fig. 9 ). [7, 8] . ER-␣36 also mediates activation of the MAPK/ERK signaling induced by anti-oestrogens, such as tamoxifen and ICI 182, 780 [7] . [7, 26] . [27] . Therefore (Fig. 1B) [32] . ER-␣36 transcripts are generated from the ER-␣66 genomic DNA through alternative promoter usage and alternative splicing [7, 8] . The transcription of ER-␣36 is initiated from a previously unidentified promoter in the first intron of the ER-␣66 genomic DNA [7, 8] 
Discussion
Recently, we identified and characterized a novel ER-␣ variant, ER-␣36 that mediates membrane-initiated mitogenic oestrogen signaling through activation of the MAPK/ERK pathway
Transient co-transfection of ER-␣36 and ER-␣66 demonstrated that ER-␣66 suppresses ER-␣36 promoter activity in an oestrogen-independent manner
